» Articles » PMID: 26773500

Human Gb3/CD77 Synthase Reveals Specificity Toward Two or Four Different Acceptors Depending on Amino Acid at Position 211, Creating P(k), P1 and NOR Blood Group Antigens

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2016 Jan 17
PMID 26773500
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Human Gb3/CD77 synthase (α1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(α1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. Recently, it was shown that c.631C > G mutation in A4GALT, which causes p.Q211E substitution in the open reading frame of the enzyme, broadens the enzyme specificity, making it able also to synthesize Gal(α1-4)GalNAc moiety, which constitutes the defining terminal disaccharide of the NOR antigen (carried by two glycosphingolipids: NOR1 and NOR2). Terminal Gal(α1-4)Gal disaccharide is also present in another glycosphingolipid blood group antigen, called P1, which together with P(k) and NOR comprises the P1PK blood group system. Despite several attempts, it was never clearly shown that P1 antigen is synthesized by Gb3/CD77 synthase, leaving open an alternative hypothesis that there are two homologous α1,4-galactosyltransferases in humans. In this study, using recombinant Gb3/CD77 synthase produced in insect cells, we show that the consensus enzyme synthesizes both the P(k) and P1 antigens, while its p.Q211E variant additionally synthesizes the NOR antigen. This is the first direct biochemical evidence that Gb3/CD77 synthase is able to synthesize two different glycosphingolipid antigens: P(k) and P1, and when p.Q211E substitution is present, the NOR antigen is also synthesized.

Citing Articles

Human Gb3/CD77 synthase: a glycosyltransferase at the crossroads of immunohematology, toxicology, and cancer research.

Szymczak-Kulus K, Czerwinski M, Kaczmarek R Cell Mol Biol Lett. 2024; 29(1):137.

PMID: 39511480 PMC: 11546571. DOI: 10.1186/s11658-024-00658-7.


ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies.

Jajosky R, Wu S, Zheng L, Jajosky A, Jajosky P, Josephson C iScience. 2023; 26(1):105798.

PMID: 36691627 PMC: 9860303. DOI: 10.1016/j.isci.2022.105798.


Comparative analysis of antigen coding genes in 15 red cell blood group systems of Yunnan Yi nationality in China: A cross-sectional study.

He K, Xu L, Hu Y, Xu Y, Zhao Y, Bao J Health Sci Rep. 2022; 5(6):e891.

PMID: 36262810 PMC: 9576115. DOI: 10.1002/hsr2.891.


Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions.

Kok K, Zwiers K, Boot R, Overkleeft H, Aerts J, Artola M Biomolecules. 2021; 11(2).

PMID: 33673160 PMC: 7918333. DOI: 10.3390/biom11020271.


Human Gb3/CD77 synthase produces P1 glycotope-capped N-glycans, which mediate Shiga toxin 1 but not Shiga toxin 2 cell entry.

Szymczak-Kulus K, Weidler S, Bereznicka A, Mikolajczyk K, Kaczmarek R, Bednarz B J Biol Chem. 2021; 296:100299.

PMID: 33460651 PMC: 7949097. DOI: 10.1016/j.jbc.2021.100299.